Exhibit 99.1

FOR IMMEDIATE RELEASE

Contact:

Chris Lewis

Vice President, Investor Relations & Corporate Affairs

(949) 481-0510

[email protected]

Glaukos Corporation Announces Second Quarter 2022 Financial Results

Aliso Viejo, CA – August 3, 2022 – Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the second quarter ended June 30, 2022. Key highlights include:

“I’m pleased with our second quarter performance and solid execution of our strategies despite a challenging global environment,” said Thomas Burns, Glaukos chairman and chief executive officer. “We are now in the midst of several exciting new product launches and continue to successfully invest in and advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.”

Second Quarter 2022 Financial Results

Net sales in the second quarter of 2022 were $72.7 million, compared to $78.1 million in the same period in 2021.

Gross margin for the second quarter of 2022 was approximately 75%, compared to approximately 77% in the same period in 2021. Non-GAAP gross margin for the second quarter of 2022 was approximately 83%, compared to approximately 84% in the same period in 2021.

Selling, general and administrative (SG&A) expenses for the second quarter of 2022 increased 10% to $49.9 million, compared to $45.3 million in the same period in 2021. Non-GAAP SG&A expenses for the second quarter of 2022 increased 12% to $49.0 million, compared to $43.6 million in the same period in 2021.

Research and development (R&D) expenses for the second quarter of 2022 increased 31% to $31.7 million, compared to $24.3 million in the same period in 2021. Non-GAAP R&D expenses for the second quarter of 2022 increased 31% to $31.7 million, compared to $24.1 million in the same period in 2021

.

1

In addition, during the second quarter of 2022, the company incurred a $10.0 million in-process R&D (IPR&D) charge associated with an upfront payment related to the execution of a licensing arrangement with iVeena Delivery Systems, Inc., compared to a $5.0 million IPR&D charge incurred in the second quarter of 2021 associated with an upfront payment related to the execution of an amended licensing arrangement with Intratus, Inc. These charges were included in both GAAP and non-GAAP operating expenses, which is a change versus the company’s previous methodology where similar IPR&D transactions were excluded for non-GAAP disclosure and reporting purposes. This change is the result of the U.S. Securities and Exchange Commission’s most recent industry correspondence on this matter.

Loss from operations in the second quarter of 2022 was $36.8 million, compared to operating loss of $14.2 million in the second quarter of 2021. Non-GAAP loss from operations in the second quarter of 2022 was $30.4 million, compared to non-GAAP operating loss of $6.8 million in the second quarter of 2021. Included in the non-GAAP loss from operations figures are IPR&D charges of $10.0 million and $5.0 million in the second quarter of 2022 and 2021, respectively.

Net loss in the second quarter of 2022 was $45.5 million, or ($0.96) per diluted share, compared to a net loss of $17.5 million, or ($0.38) per diluted share, in the second quarter of 2021. Non-GAAP net loss in the second quarter of 2022 was $39.1 million, or ($0.83) per diluted share, compared to non-GAAP net loss of $10.1 million, or ($0.22) per diluted share, in the second quarter of 2021. Included in the non-GAAP net loss figures are IPR&D charges of $10.0 million and $5.0 million in the second quarter of 2022 and 2021, respectively, which caused the non-GAAP loss per diluted share to have an additional loss of ($0.21) and ($0.11) in each of these respective periods.

The company ended the second quarter of 2022 with approximately $400 million in cash and cash equivalents, short-term investments and restricted cash.

2022 Revenue Guidance

The company expects 2022 net sales to be in the range of $275 million to $280 million.

Webcast & Conference Call

The company will host a conference call and simultaneous webcast today at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results and provide additional information about the company’s financial outlook. A link to the webcast is available on the company’s website at http://investors.glaukos.com. To participate in the conference call, please dial 888-210-2212 (U.S.) or 646-960-0390 (international) and enter Conference ID 7935742. A replay of the webcast will be archived on the company’s website following completion of the call.

Quarterly Summary Document

The company has posted a document on its Investor Relations website under the “Financials & Filings – Quarterly Results” section titled “Quarterly Summary.” This Quarterly Summary document is designed to provide the investment community with a summarized and easily accessible reference document that details the key facts associated with the quarter, the state of the company’s business objectives and strategies and any forward statements or guidance the company may make. Going forward, this document will be provided alongside the company’s earnings press release and is designed to be read by investors before the regularly

2

scheduled quarterly conference call. As such, today’s conference call will be in a format primarily consisting of a questions and answers session, during which Glaukos will address any queries investors have regarding the company’s results. It is the company’s goal that this format will make its quarterly earnings process more efficient and impactful for the investment community going forward.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012, and has since developed a portfolio of technologically distinct and leverageable platforms to support ongoing pharmaceutical and medical device innovations. Products or product candidates for each of these platforms are designed to advance the standard of care through better treatment options across the areas of glaucoma, corneal disorders and retinal diseases.

Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of federal securities laws. All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are based on management’s current expectations, assumptions, estimates and beliefs. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this press release. These potential risks and uncertainties that could cause actual results to differ materially from those described in forward-looking statements include, without limitation, uncertainties regarding the duration and severity of the COVID-19 pandemic and its impact on our business; the impact of general macroeconomic conditions; the reduced physician fee and ASC facility fee reimbursement rate finalized by CMS for 2022 for procedures utilizing the Company’s iStent family of products and its impact on our U.S. combo-cataract glaucoma revenue; our ability to continue to generate sales of our commercialized products and develop and commercialize additional products; our dependence on a limited number of third-party suppliers, some of which are single-source, for components of our products; the occurrence of a crippling accident, natural disaster, or other disruption at our primary facility, which may materially affect our manufacturing capacity and operations; securing or maintaining adequate coverage or reimbursement by third-party payors for procedures using the iStent, the iStent inject, the iStent inject W, iAccess, iPRIME, iStent infinite, our corneal cross-linking products or other products in development; our ability to properly train, and gain acceptance and trust from ophthalmic surgeons in the use of our products; our ability to compete effectively in the medical device industry and against current and future technologies (including MIGS technologies); our compliance with federal, state and foreign laws and regulations for the approval and sale and marketing of our products and of our manufacturing processes; the lengthy and expensive clinical trial process and the uncertainty of timing and outcomes from any particular clinical trial or regulatory approval processes; the risk of recalls or serious safety issues with our products and the uncertainty of patient outcomes; our ability to protect, and the expense and time-consuming nature of protecting our intellectual property against third parties and competitors and the impact of any claims against us for infringement or misappropriation of third party intellectual property rights and any related litigation; and

3

our ability to service our indebtedness. These and other known risks, uncertainties and factors are described in detail under the caption “Risk Factors” and elsewhere in our filings with the Securities and Exchange Commission (SEC), including our Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, which was filed with the SEC on May 5, 2022, and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, which is expected to be filed with the SEC by August 9, 2022. Our filings with the SEC are available in the Investor Section of our website at www.glaukos.com or at www.sec.gov. In addition, information about the risks and benefits of our products is available on our website at www.glaukos.com. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.

Statement Regarding Use of Non-GAAP Financial Measures

To supplement the consolidated financial results prepared in accordance with Generally Accepted Accounting Principles (“GAAP”), the Company uses certain non-GAAP historical financial measures. Management makes adjustments to the GAAP measures for items (both charges and gains) that (a) do not reflect the core operational activities of the Company, (b) are commonly adjusted within the Company’s industry to enhance comparability of the Company’s financial results with those of its peer group, or (c) are inconsistent in amount or frequency between periods (albeit such items are monitored and controlled with equal diligence relative to core operations). The Company uses the term “Non-GAAP” to exclude external acquisition-related costs incurred to effect a business combination; amortization of intangible assets acquired in a business combination, asset purchase transaction or other contractual relationship; impairment of goodwill and intangible assets; certain in-process R&D charges; fair value adjustments to contingent consideration liabilities and pre-acquisition contingencies arising from a business combination; integration and transition costs related to business combinations; fair market value adjustments to inventories acquired in a business combination or asset purchase transaction; restructuring charges, duplicative operating expenses, or asset write-offs (or reversals) associated with exiting or significantly downsizing a business; gain or loss from the sale of a business; gain or loss on the mark-to-market adjustment, impairment, or sale of long-term investments; mark-to-market adjustments on derivative instruments that hedge income or expense exposures in a future period; significant legal litigation costs and/or settlement expenses or proceeds legal and other associated expenses that are both unusual and significant related to governmental or internal inquiries; and significant discrete income and other tax adjustments related to transactions as well as changes in estimated acquisition-date tax effects associated with business combinations, and the impact from implementation of tax law changes and settlements. See “GAAP to Non-GAAP Reconciliations” for a reconciliation of each non-GAAP measure presented to the comparable GAAP financial measure.

​

​

4

GLAUKOS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

(in thousands, except per share amounts)

​

​

5

GLAUKOS CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except par values)

​

​

6

GLAUKOS CORPORATION

GAAP to Non-GAAP Reconciliations

(in thousands, except per share amounts and percentage data)

(unaudited)

Note: Beginning this quarter, we are no longer excluding certain in-process R&D charges for non-GAAP reporting and disclosure purposes in response to and in accordance with the Securities and Exchange Commission’s latest indsutry correspondance on this matter. We have conformed all prior period amounts included herein to this new presentation.

​

7

GLAUKOS CORPORATION

GAAP to Non-GAAP Reconciliations

(in thousands, except per share amounts and percentage data)

(unaudited)

​

Note: Beginning this quarter, we are no longer excluding certain in-process R&D charges for non-GAAP reporting and disclosure purposes in response to and in accordance with the Securities and Exchange Commission’s latest industry correspondance on this matter. We have conformed all prior period amounts included herein to this new presentation.

​

8

9

Exhibit 99.2

​

​

GLAUKOS CORPORATION (NYSE: GKOS)

SECOND QUARTER 2022 IN REVIEW

​

Important Information

​

This document is intended to be read by investors in advance of regularly scheduled quarterly conference calls and was designed to provide a review of Glaukos Corporation’s recent financial and operational performance and general business outlook.

Please see “Forward-Looking Statements” and “Statement Regarding Use of Non-GAAP Financial Measures” in the Additional Information section of this document.

Conference Call Information

​

​

​

​

1

​

​

SECOND QUARTER 2022 FINANCIAL RESULTS SUMMARY

​

​

See “Statement Regarding Use of Non-GAAP Financial Measures” and the Non-GAAP reconciliations included within the Additional Information section of this document. Reconciliations for each of constant currency revenue growth, Non-GAAP Gross Margin, Non-GAAP OPEX, and Non-GAAP Earnings Per Share to the most directly comparable GAAP financial measure are provided.

​

2

​

Revenue Performance & Commercial Overview

​

Global Consolidated Revenue Performance

Glaukos reported second quarter net revenues of $72.7 million that were down 7% versus the second quarter of 2021 on a reported basis or down 5% on a constant currency basis versus 2Q 2021. As a reminder, 2Q 2021 was a challenging comparable period as it was the strongest of the year for most of our Med Tech peers and Glaukos. On a sequential basis, we delivered QoQ reported growth of 7%, or 9% on a constant currency basis, versus 1Q 2022. Our second quarter performance reflected continued execution across our global Glaucoma and Corneal Health franchises amidst U.S. combination-cataract glaucoma headwinds associated with the 2022 CMS Physician Fee reimbursement cut, foreign exchange headwinds internationally, sporadic commercial payor reimbursement challenges in our Corneal Health franchise, and COVID dynamics globally.

​

Franchise Revenue Performance

​

3

​

U.S. Glaucoma

Our second quarter U.S. Glaucoma net revenues were approximately $38.2 million, down 18% year-over-year on a tough comparison but up 13% quarter-over-quarter reflecting a combination of pandemic-related disruptions and the 2022 CMS final Physician Fee reimbursement cuts. Despite the impact of these dynamics, as expected, we’ve been very pleased with the execution of our commercial strategies and the resiliency of our combo-cataract iStent® franchise in the face of the reimbursement headwinds thus far in 2022.

We remain focused on innovating and expanding the sight-saving tools available to surgeons to improve overall care for ophthalmic patients. One such new technology is iAccess™, our trabecular trephine device, for which we commenced full U.S. commercial launch activities in the latter part of the first quarter. Initial feedback from surgeons who have performed a goniotomy with iAccess has been positive where they most commonly cite the technology’s differentiated tissue-sparing approach to creating an extensive opening to Schlemm’s canal across multiple clock hours. Surgeon adoption and utilization of iAccess continues to grow and market feedback remains positive. During the latter part of the second quarter, we also commenced initial commercial launch activities for iPRIME™, our innovative new viscoelastic delivery device. While we remain in the very early stages of iPRIME’s controlled launch, this novel tool adds to our expanding portfolio of minimally-invasive solutions designed to grow and improve treatment options for our surgeon customers and patients.

We acknowledge that we will continue to face near-term headwinds in combination-cataract glaucoma domestically based on the cuts in professional reimbursement for trabecular stents that remain substantially below more invasive alternatives, and as such, we will remain prudent as it relates to forward guidance as we navigate the year ahead but continue to feel confident in our ability to execute our strategy as we continue to bring complementary technologies to market in the quarters ahead.

International Glaucoma

Our second quarter International Glaucoma net revenues were approximately $17.9 million, representing year-over-year growth of 9%, or 20% on a constant currency basis, versus 2Q 2021. Growth internationally during the second quarter was broad-based, but somewhat offset by intermittent COVID disruptions and most notably unfavorable foreign exchange headwinds. Early launch activities of the PRESERFLO® MicroShunt® in Australia and Canada continue to go well and our overall performance in key markets such as Japan and France highlighted the strong quarter. We remain early in our penetration of the international opportunity and continue to make significant investments in our commercial sales and market access efforts in existing markets globally while selectively pursuing geographic expansion opportunistically.

Corneal Health

Our second quarter Corneal Health net revenues were approximately $16.6 million, representing year-over-year growth of 8% versus 2Q 2021. The second quarter performance was driven by U.S. Photrexa® sales of $13.5 million along with a continued trend of healthy new U.S. Photrexa account starts, partially offset by sporadic reimbursement volatility. This type of commercial payor reimbursement volatility is not uncommon in rare diseases such as keratoconus. In response, we are proactively adjusting resources and increasing our market access coverage of commercial payors to support our goal to improve access to care for keratoconus patients.

​

4

​

Additional Commercial Updates & Commentary

We have had several additional positive commercial updates worth highlighting here:

​

Developed by Glaukos in partnership with ophthalmic surgeons, iAccess is designed to deliver outflow through the trabecular meshwork into Schlemm’s canal. When medically necessary, goniotomy with iAccess is designed to be unrestricted in its ability to provide an extensive opening to Schlemm’s canal while preserving up to 95% more anatomy vs other tissue removal procedures.

​

​

​

iPRIME is a novel, truly minimally-invasive viscoelastic delivery system that further supports the needs of physicians and patients by providing the delivery of viscoelastic during ophthalmic surgery. This technology further expands Glaukos’ broad portfolio of innovative ophthalmic solutions and is consistent with our longstanding position on the value of minimally-invasive therapies. We believe iPRIME will be another important tool that supports the needs of physicians and patients.

​

​

​

The iStent infinite is a three-stent device designed for use in a standalone procedure to reduce elevated IOP in glaucoma patients. It includes three heparin-coated titanium stents preloaded into an auto-injection system that allows the surgeon to inject stents across a span of up to approximately six clock hours around Schlemm’s canal, the eye’s primary drainage channel. Once in place, the stents are designed to lower IOP by restoring the natural, physiological outflow of aqueous humor. Supported by strong pivotal data highlighting favorable safety and effectiveness, we believe iStent infinite may provide ophthalmic surgeons with a compelling new treatment alternative in a standalone procedure for patients with open-angle glaucoma uncontrolled by prior surgical and medical therapy.

​

5

​

2022 Updated Revenue Guidance

Glaukos expects full year 2022 global consolidated net sales of $275 - $280 million, up from its previous guidance of $270 - $275 million. This upwardly-revised guidance attempts to take into consideration:

​

We would also remind investors to factor in our typical underlying seasonality patterns and COVID-related trends and risks that are outside of our control.

​

6

​

Research & Development / Pipeline Overview

Pipeline Summary

Our five key dropless technology therapy platforms designed to disrupt traditional treatment paradigms and generate cascades of future innovation are as follows:

5

​

​	​
​	iStent® micro-scale surgical devices
1 ​	iDose® sustained-release pharmaceuticals
2 ​	iLution™ transdermal pharmaceuticals
3 ​	iLink™ bio-activated pharmaceuticals
4 ​	Retina XR™ bio-erodible sustained-release pharmaceuticals

​

7

​

Key R&D and Pipeline Updates

We are continuing to successfully invest in and advance our fulsome pipeline of core novel platforms, supported by over $350 million of self-funded investment into our R&D programs since 2018 alone. Recent updates in our pipeline include:

​

8

​

Other Financial Performance Overview

As a reminder, we discuss our financial performance on a non-GAAP or pro forma basis and summarize our GAAP performance. We encourage investors to review our GAAP to non-GAAP reconciliation which can be found in our earnings press release, the Additional Information section contained herein, as well as the Investor Relations section of our website.

Second quarter 2022 financial performance summary:

​

​	2022: ($30.4M) 2021: ($6.8M) ​ Loss (Non-GAAP) 2022: ($39.1M) 2021: ($10.1M) ​ EPS (Non-GAAP) 2022: ($0.83) 2021: ($0.22) ​ ​	($30.4M)             ($10.0M) ($20.4M) ​ 2022 Net Loss:      ($39.1M)             ($10.0M) ($29.1M) ​ 2022 EPS:      ($0.83)             ($0.21) ($0.62) ​	($6.8M)               ($5.0M) ($1.8M) ​ 2021 Net Loss:        ($10.1M)               ($5.0M) ($5.1M) ​ 2Q 2021 EPS:        ($0.22)               ($0.11) ($0.11) ​
Gross Margin (Non-GAAP) ​	2Q 2022: 83% 2Q 2021: 84% YoY ∆: -130bps	· Please note that our non-GAAP adjustments to cost of goods sold include substantial amounts related to Avedro acquisition accounting · YoY decrease reflects impacts of geographic mix, FX and inflation
SG&A (Non-GAAP) ​	2Q 2022: $49.0M 2Q 2021: $43.6M YoY ∆: +12%	· 14% sequential increase vs $43.1M in 1Q 2022 · YoY and QoQ increases reflect commercial and G&A investments globally and new product launch activities
R&D (Non-GAAP) ​	2Q 2022: $31.7M 2Q 2021: $24.1M YoY ∆: +31%	· 19% sequential increase vs $26.8M in 1Q 2022 · YoY and QoQ increases reflect continued investment in and advancement of R&D programs and clinical trial activities
SG&A + R&D (Non-GAAP) ​ ​	2Q 2022: $80.8M 2Q 2021: $67.8M YoY ∆: +19%	· 16% sequential increase vs $69.8M in 1Q 2022
Earnings* ​ ​	Op Loss (Non-GAAP) 2Q 2022: ($30.4M) 2Q 2021: ($6.8M) ​ Net Loss (Non-GAAP) 2Q 2022: ($39.1M) 2Q 2021: ($10.1M) ​ Diluted EPS (Non-GAAP) 2Q 2022: ($0.83) 2Q 2021: ($0.22) ​	2Q 2022 Operating Loss: Non-GAAP:     ($30.4M) IPR&D:            ($10.0M)                          ($20.4M) ​ 2Q 2022 Net Loss: Non-GAAP:     ($39.1M) IPR&D:            ($10.0M)                          ($29.1M) ​ 2Q 2022 EPS: Non-GAAP:     ($0.83) IPR&D:            ($0.21)                          ($0.62)	2Q 2021 Operating Loss: Non-GAAP:       ($6.8M) IPR&D:              ($5.0M)                            ($1.8M) ​ 2Q 2021 Net Loss: Non-GAAP:       ($10.1M) IPR&D:              ($5.0M)                            ($5.1M) ​ 2Q 2021 EPS: Non-GAAP:       ($0.22) IPR&D:              ($0.11)                            ($0.11)
*Non-GAAP figures include a $10 million and a $5 million in-process R&D charge associated with upfront payments related to the execution of licensing agreements in 2Q 2022 and 2Q 2021, respectively. Beginning this quarter, we are no longer excluding certain in-process R&D charges for non-GAAP reporting and disclosure purposes, in response to and accordance with the Securities and Exchange Commission’s (SEC) most recent industry correspondence on this matter. In light of this recent change in presentation of our non-GAAP financial measures, we believe disclosure of the additional information provided above will help investors understand the impact of these charges on the Company’s operating results and facilitate a comparison of the Company’s results of operations to prior periods when such charges were excluded from the Company’s non-GAAP financial measures.

9

​

CapEx ​	2Q 2022: $9.4M 2Q 2021: $11.4M YoY ∆: ($2.0M) ​	· Capital expenditures remained elevated versus historical levels, a trend expected to continue before moderating to levels more consistent with historical norms over the course of 2023 · 2Q YoY decline primarily due to the substantial completion of new Aliso Viejo, CA facilities
Cash ​	2Q 2022: ~$400M 1Q 2022: ~$425M QoQ ∆: ($25M) ​ ​	· Operating expenses and elevated capital investments ​ ​

​

Other Important Updates

​

​

10

​

​

​

​

11

​

Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of federal securities laws. All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are based on management’s current expectations, assumptions, estimates and beliefs. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this presentation. These potential risks and uncertainties that could cause actual results to differ materially from those described in forward-looking statements include, without limitation, uncertainties regarding the duration and severity of the COVID-19 pandemic and its impact on our business; the impact of general macroeconomic conditions; the reduced physician fee and ASC facility fee reimbursement rate finalized by CMS for 2022 for procedures utilizing the Company’s iStent family of products and its impact on our U.S. combo-cataract glaucoma revenue; our ability to continue to generate sales of our commercialized products and develop and commercialize additional products; our dependence on a limited number of third-party suppliers, some of which are single-source, for components of our products; the occurrence of a crippling accident, natural disaster, or other disruption at our primary facility, which may materially affect our manufacturing capacity and operations; securing or maintaining adequate coverage or reimbursement by third-party payors for procedures using the iStent, the iStent inject, the iStent inject W, iAccess, iPRIME, iStent infinite, our corneal cross-linking products or other products in development; our ability to properly train, and gain acceptance and trust from ophthalmic surgeons in the use of our products; our ability to compete effectively in the medical device industry and against current and future technologies (including MIGS technologies); our compliance with federal, state and foreign laws and regulations for the approval and sale and marketing of our products and of our manufacturing processes; the lengthy and expensive clinical trial process and the uncertainty of timing and outcomes from any particular clinical trial or regulatory approval processes; the risk of recalls or serious safety issues with our products and the uncertainty of patient outcomes; our ability to protect, and the expense and time-consuming nature of protecting our intellectual property against third parties and competitors and the impact of any claims against us for infringement or misappropriation of third party intellectual property rights and any related litigation; and our ability to service our indebtedness. These and other known risks, uncertainties and factors are described in detail under the caption “Risk Factors” and elsewhere in our filings with the Securities and Exchange Commission (SEC), including our Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, which was filed with the SEC on May 5, 2022, and will also be included in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, which we expect to file on or before August 9, 2022. Our filings with the SEC are available in the Investor Section of our website at www.glaukos.com or at www.sec.gov. In addition, information about the risks and benefits of our products is available on our website at www.glaukos.com. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.

​

12

​

Statement Regarding Use of Non-GAAP Financial Measures

To supplement the consolidated financial results prepared in accordance with Generally Accepted Accounting Principles ("GAAP"), the Company uses certain non-GAAP historical financial measures. Management makes adjustments to the GAAP measures for items (both charges and gains) that (a) do not reflect the core operational activities of the Company, (b) are commonly adjusted within the Company's industry to enhance comparability of the Company's financial results with those of its peer group, or (c) are inconsistent in amount or frequency between periods (albeit such items are monitored and controlled with equal diligence relative to core operations). The Company uses the term "Non-GAAP" to exclude external acquisition-related costs incurred to effect a business combination; amortization of intangible assets acquired in a business combination, asset purchase transaction or other contractual relationship; impairment of goodwill and intangible assets; certain in-process R&D charges; fair value adjustments to contingent consideration liabilities and pre-acquisition contingencies arising from a business combination; integration and transition costs related to business combinations; fair market value adjustments to inventories acquired in a business combination or asset purchase transaction; restructuring charges, duplicative operating expenses, or asset write-offs (or reversals) associated with exiting or significantly downsizing a business; gain or loss from the sale of a business; gain or loss on the mark-to-market adjustment, impairment, or sale of long-term investments; mark-to-market adjustments on derivative instruments that hedge income or expense exposures in a future period; significant legal litigation costs and/or settlement expenses or proceeds legal and other associated expenses that are both unusual and significant related to governmental or internal inquiries; and significant discrete income and other tax adjustments related to transactions as well as changes in estimated acquisition-date tax effects associated with business combinations, and the impact from implementation of tax law changes and settlements. In addition, we also present certain revenue information on a constant currency basis to exclude fluctuations in currency exchange rates that impact the comparative results and sales growth rates of the Company's business as compared to historical financial results. See “Primary GAAP to Non-GAAP Reconciliations” for a reconciliation of each non-GAAP measure presented to the comparable GAAP financial measure.

​

​

13

​

GAAP Income Statement

GLAUKOS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

(in thousands, except per share amounts)

​

​

14

​

GAAP Balance Sheet

GLAUKOS CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except par values)

​

15

​

Primary GAAP to Non-GAAP Reconciliations

GLAUKOS CORPORATION

GAAP to Non-GAAP Reconciliations

(in thousands, except per share amounts and percentage data)

(unaudited)

​